Rescuing NKCC1 hyperfunction using the NKCC1 antagonist and new generation short-acting diuretic bumetanide (BTN) has been effective in its off-label use in a wide range of neurological and psychiatric pathologies including Rett syndrome, autism, chronic pain, and epilepsy [63, 72]. This evidence concerns the gene SLC12A2 and Rett syndrome.